Adicet Bio, Inc.

NASDAQ:ACET

Biotechnology

Healthcare
$5.53 +0.25%

+$0.02 today

Market cap
$51.70M
Beta
1.57
P/E (TTM)
-0.8
EPS (TTM)
-$10.13
52W Low $6.01High $17.44

Volume 0.15M

Average 0.12M

ACET Common Stock Repurchased

Cash spent buying back the company's own shares.

Adicet Bio, Inc.NASDAQ: ACET

Common Stock Repurchased · Q1 FY2026 · quarter ended Mar 2026

Common stock repurchased turns positive

Q1 FY2026 common stock repurchased was $0, compared with -$104 a year earlier. Trailing-twelve-month common stock repurchased was $0.

Context

  • Common stock repurchased increased in 0 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly common stock repurchased holds near $0 or moves back toward the trailing-twelve-month quarterly average of $0.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterMar 2026
$0— QoQ
Last fiscal yearDec 2025
$0— YoY
LTMMar 2026
$0+100.0% YoY
Common Stock Repurchased past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+100.0%——
1 year———
3-year CAGR———
5-year CAGR——
10-year CAGR——

Common Stock Repurchased history

USD · from the cash flow

Latest · FY2025
0 USD
Year-over-year change
—

Common Stock Repurchased vs competitors

How ACET compares with its peers on the latest reported figures

  • ACET's LTM Mar 2026 common stock repurchased of $0 is the 3rd largest of the 8 companies compared; the peer median is $0.
  • Its year-over-year change of +100.0% is the highest of 2, against a peer median of +100.0%.
ACET Competitors Peer median
Common Stock Repurchased for ACET and competitors
Company Period LTM YoY 3-year CAGR% of revenue
TCRXTScan Therapeutics, Inc.LTM Mar 2026$191K ——2.1%
IMUXImmunic, Inc.LTM Mar 2026$123K ———
ACETAdicet Bio, Inc.LTM Mar 2026$0 +100.0%——
ADAGAdagene Inc.LTM Jun 2024$0 ——0.0%
ACRVAcrivon Therapeutics, Inc. Common StockLTM Mar 2026$0 ———
GANXGain Therapeutics, Inc.LTM Mar 2026$0 ———
NRXPNRx Pharmaceuticals, Inc.LTM Mar 2026$0 ——0.0%
HOWLWerewolf Therapeutics, Inc.LTM Jun 2026$0 +100.0%—0.0%
Peer median (excluding ACET) $0+100.0%—0.0%

Competitors are the stored peer set for ACET. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income(62M)(69.79M)(142.66M)(117.12M)(116.8M)
Depreciation & Amortization1.54M2.58M6.1M6.47M2.29M
Deferred Income Tax1.23M0000
Stock-Based Compensation12.51M17.13M20.26M22.23M14.27M
Change in Working Capital(6.06M)2.74M252K(5.53M)1.47M
Accounts Receivables(30K)185K000
Inventory2.01M0000
Accounts Payables1.14M1.71M(1.68M)1.11M1.03M
Other Working Capital(9.18M)849K1.94M(6.63M)444K
Other Non-Cash Items1.72M2.58M22.33M1.57M3.53M
Operating Cash Flow(51.05M)(44.77M)(93.72M)(92.38M)(95.25M)
Capital Expenditures(13.05M)(16.78M)(4.46M)(1.12M)(1.74M)
Acquisitions (Net)00000
Purchases of Investments000(129.12M)(140.87M)
Sales of Investments10.25M0011M145M
Other Investing Activities00000
Investing Cash Flow(2.8M)(16.78M)(4.46M)(119.24M)2.39M
Debt Repayment0000(150K)
Common Stock Issued238.13M43.36M386K110.92M75.17M
Common Stock Repurchased00000
Dividends Paid00000
Other Financing Activities4.56M(1.85M)(150K)389K(104K)
Financing Cash Flow242.69M41.51M236K111.31M75.25M
Effect of Forex Changes00000
Net Change in Cash188.84M(20.04M)(97.95M)(100.31M)(17.61M)
Free Cash Flow(64.1M)(61.55M)(98.18M)(93.5M)(96.98M)

Adicet Bio, Inc.

NASDAQ:ACET

Intrinsic Alpha fair value

Locked

Current Price

$5.53

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.